PYK2 crystal structure and uses
First Claim
Patent Images
1. A method for identifying compounds binding to PYK2, comprising determining the orientation of at least one compound bound with PYK2 in co-crystals of PYK2 with said compound.
1 Assignment
0 Petitions
Accused Products
Abstract
A crystal structure of PYK2 is described that was determined by X-ray crystallography. The use of PYK2 crystals and strucural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate PYK2.
235 Citations
98 Claims
-
1. A method for identifying compounds binding to PYK2, comprising
determining the orientation of at least one compound bound with PYK2 in co-crystals of PYK2 with said compound.
-
8. A method for obtaining improved ligands binding to PYK2, comprising
identifying a compound that binds to PYK2 and determining whether said compound interacts with one or more of PYK2 residues 503, 505, 457, 488, 567, and 554; determining whether a derivative of said compound binds to PYK2 with greater affinity or greater specificity or both than said compound, wherein binding with greater affinity or greater specificity or both indicates that said derivative is an improved ligand. - View Dependent Claims (9, 10, 11)
-
12. A method for developing ligands specific for PYK2, comprising
identifying a compound that binds to a plurality of kinases; - and
determining whether a derivative of said compound has greater specificity for PYK2 than said compound. - View Dependent Claims (13, 14, 15, 16)
- and
- 17. A crystalline form of PYK2 kinase domain.
- 24. A method for obtaining a crystal of PYK2, comprising subjecting PYK2 protein at 5-20 mg/ml to crystallization condition substantially equivalent to 2-10% polyethylene glycol (PEG) 8000, 0.2 M sodium acetate, 0.1% sodium cacodylate pH 6.5, 20% glycerol for a time sufficient for cystal development.
- 28. A co-crystal of PYK2 and a PYK2 binding compound.
- 32. A method for obtaining co-crystals of PYK2 with a binding compound, comprising subjecting PYK2 protein at 5-20 mg/ml to crystallization conditions 2-10% polyethylene glycol (PEG) 8000, 0.2 M sodium acetate, 0.1% sodium cacodylate pH 6.5, 20% glycerol in the presence of binding compound for a time sufficient for cystal development.
-
36. A method for determining a structure of a kinase, comprising
creating a homology model from an electronic representation of a PYK2 structure.
- 41. An electronic representation of a crystal structure of PYK2.
- 46. An electronic representation of a binding site of PYK2.
- 52. An electronic representation of a PYK2 based homology model for a kinase.
-
55. A method for identifying a ligand binding to PYK2, comprising
determining whether a derivative compound that includes a core structure of Formula I binds to PYK2 with altered binding affinity or specificity or both as compared to the parent compound.
-
56. A method for modulating PYK2 activity, comprising
contacting PYK2 with a compound that binds to PYK2 and interacts with three or more of residues 503, 505, 457, 488, 567, and 554.
-
59. A method for treating a patient suffering from a disease or condition characterized by abnormal PYK2 activity, comprising
administering to said patient a compound that interacts with three or more of PYK2 residues 503, 505, 457, 488, 567, and 554.
-
64. An electronic representation of a modified PYK2 crystal structure, comprising
an electronic representation of the atomic coordinates of a modified PYK2.
-
66. A method for developing a biological agent, comprising
analyzing a PYK2 crystal structure and identifying at least one sub-structure for forming a said biological agent.
-
72. A method for identifying potential PYK2 binding compounds, comprising
fitting at least one electronic representation of a compound in an electronic representation of a PYK2 binding site.
-
79. A method for attaching a PYK2 binding compound to an attachment component, comprising
identifying energetically allowed sites for attachment of a said attachment component on a kinase binding compound; - and
attaching said compound or derivative thereof to said attachment component at said energetically allowed site. - View Dependent Claims (78, 80, 81, 82, 83, 84, 85, 86, 87)
- and
-
88. A modified compound, comprising
a compound of Formula I, with a linker moiety attached thereto at an energetically allowed site for binding of said modified compound to PYK2.
-
92. A method for developing a ligand for a kinase comprising conserved residues matching one or more of PYK2 residues residues 503, 505, 457, 488, 567, and 554, comprising
determining whether a compound of Formula I binds to said kinase and interacts with said residue.
Specification